A multicenter clinical study of Ba qi ling mao formulation in the treatment of BCLC B / C stage of primary liver cancer
- Conditions
- primary liver cancer
- Registration Number
- ITMCTR2000003705
- Lead Sponsor
- Shuguang Hospial Affiliated to Shanghai University of TCM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. patients with primary liver cancer after radical resection (BCLC stage B, stage C);
2. aged 18 to 70 years;
3. The patients had not received systematic treatment before, including molecular targeted drug therapy, systemic chemotherapy, immunotherapy, etc;
4. Patients who are unable or unwilling to accept surgery or have disease progression after local treatment and cannot be operated again;
5. willing to accept Chinese medicine and/or integrated Chinese and western medicine treatment;
6. sign informed consent.
1. metastatic liver cancer patients, or concurrent with other cancer patients;
2. Patients with refractory ascites, hepatic encephalopathy, hepatorenal syndrome and other serious complications;
3. accompanied by heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract serious primary disease; Or mentally ill;
4. legally disabled persons, pregnant women or nursing women;
5. allergy or multiple drug allergy patients;
6. Currently participating in other clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1 year Survival period;
- Secondary Outcome Measures
Name Time Method objective response rate;PIVKA-II;Child-pugh grading;Abdominal ultrasound;disease control rate;liver function;MRI;AFP;Quality of Life Scale;